StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Tuesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on shares of Lipocine in a research report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price objective on the stock.

Lipocine Trading Down 1.4 %

Shares of LPCN opened at $4.80 on Tuesday. The firm has a fifty day simple moving average of $5.14 and a 200 day simple moving average of $5.43. Lipocine has a 12 month low of $2.44 and a 12 month high of $11.79. The stock has a market capitalization of $25.67 million, a price-to-earnings ratio of -6.32 and a beta of 1.24.

Lipocine (NASDAQ:LPCN) last released its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. As a group, research analysts predict that Lipocine will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP bought a new stake in Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine at the end of the most recent quarter. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.